Schedule 13D ownership disclosure

CG oncology Inc

Common Stock, $0.0001 par value per share · CUSIP: 156944100

Event date: 2025-09-11

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Longitude Capital Partners IV, LLCReported CIK 0001829169

    Shares: 3,190,463 · Class: 4.1%

  • Longitude Venture Partners IV, L.P.Reported CIK 0001787456

    Shares: 3,190,463 · Class: 4.1%

  • Longitude Prime Partners, LLCReported CIK 0001865779

    Shares: 1,471,805 · Class: 1.9%

  • Longitude Prime Fund, L.P.Reported CIK 0001865844

    Shares: 1,471,805 · Class: 1.9%

  • Patrick G. EnrightReported CIK 0001253886

    Shares: 4,662,268 · Class: 6.0%

  • Juliet Tammenoms BakkerReported CIK 0001431159

    Shares: 4,662,268 · Class: 6.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-25-207734
Form type
SCHEDULE 13D
Filer
CG Oncology, Inc.
CIK
CIK 1991792
Filed
Sep 18, 2025
Reporting period
Sep 11, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub